Nitric oxide-related compounds in patients with congenital heart defects and pulmonary hypertension

Pediatrics International

Volumn 42, Issue 3, 2000, Pages 249-254

  Kotake, Fumiaki ^a   Kobayashi, Jun ^a   Sonoda, Masaru ^b   Komoda, Tsugikazu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KYORITSU WOMEN'S UNIVERSITY   (Japan)

Author keywords

Congenital heart defects; Nitric oxide; Pulmonary hypertension

Indexed keywords

NITRIC OXIDE DONOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CORRELATION FUNCTION; FEMALE; HUMAN; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADOLESCENT; ADULT; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; NITRIC OXIDE; PULMONARY ARTERY; VASCULAR RESISTANCE;

EID: 0034046441     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2000.01219.x     Document Type: Article

References (37)

1. 1 Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
2. 2 Lerman A, Burnett Jr JC. Intact and altered endothelium in regulation of vasomotion. Circulation 1992; 86 (Suppl. III): 12-19.
3. 3 Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993; 88: 2117-22.
4. 4 Moncada S, Palmer RMJ. The L-arginine: nitric oxide pathway in the vessel wall: Nitric Oxide From L-Arginine. In: Moncada S, Higgs EA (eds). A Bioregulatory System. Elsevier, Amsterdam, 1990; 19-33.
5. 5 Isaacson TC, Hampel V, Weir EK, Nelson DP, Archer SL. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rat. J. Appl. Physiol. 1994; 76: 933-40.
6. 6 Le Cras TD, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol. 1996; 270: L164-70.
7. 7 Shaul PW, North AJ, Brannon TS et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am. J. Respir. Cell. Mol. Biol. 1995; 13: 167-74.
8. 8 Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am. J. Physiol. 1997; 272: H806-13.
9. 9 Noris M, Morigi M, Donadelli R et al. Nitric oxide synthase by cultured endothelial cells is modulated by flow conditions. Circ. Res. 1995; 76: 536-43.
10. 10 Nadaud S, Philippe M, Arnal JF, Michel JB, Soubrier F. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ. Res. 1996; 79: 857-63.
11. 11 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
12. 12 Lefer AM. Nitric oxide: Nature's naturally occurring leukocyte inhibitor. Circulation 1997; 95: 553-4.
13. 13 Wennmalm A, Benthin G, Edlund A et al. Metabolism and excretion of nitric oxide in humans: An experimental and clinical study. Circ. Res. 1993; 73: 1121-7.
14. 14 Sonoda M, Kobayashi J, Takezawa M et al. An assay method for nitric oxide-related compounds in whole blood. Anal. Biochem. 1997; 247: 417-27.
15. 15 Rabinovitch M. Pulmonary hypertension: Updating a mysterious disease. Cardiovasc. Res. 1997; 34: 268-72.
16. 16 Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J. Am. Coll. Cardiol. 1997; 30: 325-33.
17. 17 Hiramatsu T, Imai Y, Takanashi Y et al. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann. Thorac. Surg. 1997; 63: 648-52.
18. 18 Wennmalm A, Benthin G, Petersson AS. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br. J. Pharmacol. 1992; 106: 507-8.
19. 19 Evance T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ. Shock 1993; 41: 77-81.
20. 20 Shi Y, Li H, Shen C, Wang J, Qin S, Pan J. Plasma nitric oxide levels in newborn infants with sepsis. J. Pediatr. 1993; 123: 435-8.
21. 21 Leone AM, Francis PL, Rhodes P, Moncada S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem. Biophys. Res. Commun. 1994; 200: 951-7.
22. 22 Menon NK, Wolf A, Zehatgruber M, Bing RJ. An improved chemiluminescence assay suggests non nitric oxide-mediated action of lysophosphatidylcholine and acetylcholine. Proc. Soc. Exp. Biol. Med. 1989; 191: 316-19.
23. 23 Misko TP, Schilling RJ, Salvemini DS, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal. Biochem. 1993; 214: 11-16.
24. 24 Moshage H, Kok B, Huizenga JR, Jansen PLM. Nitrite and nitrate determinations in plasma: A critical evaluation. Clin. Chem. 1995; 41: 892-6.
25. 25 Henry Y, Lopoivre M, Drapier JC, Ducrocq C, Boucher J, Guissani A. EPR characterization of molecular targets for NO in mammalian cells and organelles. FASEB J. 1993; 7: 1124-34.
26. 26 Gaston B, Reilly J, Drazen JM et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl Acad. Sci. USA 1993; 90: 10 957-61.
27. 27 Keaney JF, Simon DI, Stamler JS et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J. Clin. Invest. 1993; 91: 1582-9.
28. 28 Viinikka L. Nitric oxide as a challenge for the clinical chemistry laboratory. Scand. J. Clin. Lab. Invest. 1996; 56: 577-81.
29. 29 Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol. 1986; 250: H822-7.
30. 30 Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 1986; 320: 454-6.
31. 31 Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 1987; 92: 639-44.
32. 32 Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA 1990; 87: 5193-7.
33. 33 Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am. J. Physiol. 1992; 262: H611-15.
34. 34 Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 1991; 88: 4651-5.
35. 35 Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 1994; 107: 1050-8.
36. 36 Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation 1978; 58: 1107-22.
37. 37 Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995; 333: 214-21.